- Home
- MLYS vs JMIA Comparison
MLYS vs JMIA Comparison
Compare MLYS & JMIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- JMIA
- Stock Information
- Founded
- MLYS 2019
- JMIA 2012
- Country
- MLYS United States
- JMIA Germany
- Employees
- MLYS N/A
- JMIA N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- JMIA Catalog/Specialty Distribution
- Sector
- MLYS Health Care
- JMIA Consumer Discretionary
- Exchange
- MLYS Nasdaq
- JMIA Nasdaq
- Market Cap
- MLYS 634.6M
- JMIA 573.4M
- IPO Year
- MLYS 2023
- JMIA 2019
- Fundamental
- Price
- MLYS $9.77
- JMIA $3.83
- Analyst Decision
- MLYS Strong Buy
- JMIA Buy
- Analyst Count
- MLYS 2
- JMIA 2
- Target Price
- MLYS $30.00
- JMIA $8.00
- AVG Volume (30 Days)
- MLYS 266.6K
- JMIA 2.5M
- Earning Date
- MLYS 11-11-2024
- JMIA 02-13-2025
- Dividend Yield
- MLYS N/A
- JMIA N/A
- EPS Growth
- MLYS N/A
- JMIA N/A
- EPS
- MLYS N/A
- JMIA N/A
- Revenue
- MLYS N/A
- JMIA $181,204,000.00
- Revenue This Year
- MLYS N/A
- JMIA $2.77
- Revenue Next Year
- MLYS N/A
- JMIA $5.62
- P/E Ratio
- MLYS N/A
- JMIA N/A
- Revenue Growth
- MLYS N/A
- JMIA 3.61
- 52 Week Low
- MLYS $8.58
- JMIA $2.89
- 52 Week High
- MLYS $16.91
- JMIA $15.04
- Technical
- Relative Strength Index (RSI)
- MLYS 37.52
- JMIA 45.34
- Support Level
- MLYS $9.18
- JMIA $3.68
- Resistance Level
- MLYS $9.97
- JMIA $3.88
- Average True Range (ATR)
- MLYS 0.85
- JMIA 0.18
- MACD
- MLYS -0.25
- JMIA -0.01
- Stochastic Oscillator
- MLYS 24.53
- JMIA 33.58
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.